These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36371469)

  • 21. Neurofilament light as a biomarker for motor decline in Parkinson's disease.
    Liu Y; Dou K; Xue L; Li X; Xie A
    Front Neurosci; 2022; 16():959261. PubMed ID: 36117629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of blood UCH-L1 and NfL levels with cognitive dysfunction in Parkinson's disease patients.
    Dong L; Chang Q; Ma J; Liu C; Guo D; Li X; Yang D; Fan Y; Liang K; Li D; Gu Q
    Neurosci Lett; 2023 May; 804():137219. PubMed ID: 37023526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer's disease: results from ADNI.
    Nabizadeh F; Balabandian M; Rostami MR; Kankam SB; Ranjbaran F; Pourhamzeh M;
    Aging Clin Exp Res; 2022 Oct; 34(10):2363-2372. PubMed ID: 35226303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
    Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
    Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
    Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity.
    Huang Y; Huang C; Zhang Q; Shen T; Sun J
    BMC Neurol; 2022 Jan; 22(1):39. PubMed ID: 35086487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study.
    Wang YL; Chen J; Du ZL; Weng H; Zhang Y; Li R; Jia Z; Sun M; Jiang J; Wang FZ; Xu J;
    Front Neurol; 2021; 12():695696. PubMed ID: 34557143
    [No Abstract]   [Full Text] [Related]  

  • 32. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
    Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J
    Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study.
    Peng L; Wan L; Liu M; Long Z; Chen D; Yuan X; Tang Z; Fu Y; Zhu S; Lei L; Wang C; Peng H; Shi Y; He L; Yuan H; Wan N; Hou X; Xia K; Li J; Chen C; Qiu R; Tang B; Chen Z; Jiang H
    J Neurol; 2023 Sep; 270(9):4248-4261. PubMed ID: 37184660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma Neurofilament Light Concentration Is Associated with Diffusion-Tensor MRI-Based Measures of Neurodegeneration in Early Parkinson's Disease.
    Welton T; Tan YJ; Saffari SE; Ng SYE; Chia NSY; Yong ACW; Choi X; Heng DL; Shih YC; Hartono S; Lee W; Xu Z; Tay KY; Au WL; Tan EK; Chan LL; Ng ASL; Tan LCS
    J Parkinsons Dis; 2022; 12(7):2135-2146. PubMed ID: 36057833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofilament light chain level in plasma extracellular vesicles and Parkinson's disease.
    Chung CC; Chan L; Chen JH; Bamodu OA; Hong CT
    Ther Adv Neurol Disord; 2020; 13():1756286420975917. PubMed ID: 33335563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Lerche S; Wurster I; Röben B; Zimmermann M; Machetanz G; Wiethoff S; Dehnert M; Rietschel L; Riebenbauer B; Deuschle C; Stransky E; Lieplt-Scarfone I; Gasser T; Brockmann K
    Mov Disord; 2020 Jul; 35(7):1138-1144. PubMed ID: 32445500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson's Disease.
    Imarisio A; Pilotto A; Garrafa E; Conforti F; Masciocchi S; Turrone R; Gipponi S; Cottini E; Rizzetti MC; Porrini V; Gussago C; Pizzi M; Guadagni F; Zetterberg H; Ashton NJ; Hye A; Padovani A
    Neurodegener Dis; 2021; 21(5-6):109-116. PubMed ID: 35287127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.